The Diagnostic and Prognostic Impact of Serum miRNA-21 in a Sample of Hepatitis C/None Hepatitis Diffuse Large B Cell Lymphoma Egyptian Patients — Oak Academic Publishing
Research ArticleOpen AccessGoogle Scholar indexed
The Diagnostic and Prognostic Impact of Serum miRNA-21 in a Sample of Hepatitis C/None Hepatitis Diffuse Large B Cell Lymphoma Egyptian Patients
Department of Haematology, Faculty of Medicine, Alexandria University, Alexandria, Egypt
,
Department of Haematology, Faculty of Medicine, Alexandria University, Alexandria, Egypt
,
Department of Pathology, Faculty of Medicine, Alexandria University, Alexandria, Egypt
,
Department of Clinical Pathology, Faculty of Medicine, Alexandria University, Alexandria, Egypt
,
Department of Haematology, Faculty of Medicine, Alexandria University, Alexandria, Egypt
1 Department of Haematology, Faculty of Medicine, Alexandria University, Alexandria, Egypt
2 Department of Haematology, Faculty of Medicine, Alexandria University, Alexandria, Egypt
3 Department of Pathology, Faculty of Medicine, Alexandria University, Alexandria, Egypt
4 Department of Clinical Pathology, Faculty of Medicine, Alexandria University, Alexandria, Egypt
5 Department of Haematology, Faculty of Medicine, Alexandria University, Alexandria, Egypt
Background: Circulating microRNAs are potential biomarkers of diagnostic and prognostic impact in various inflammatory and malignant diseases. Aim: Linking inflammation with malignancy, we studied miRNA-21 in sera of hepatitis-C-virus (HCV) and none hepatitis diffuse large B-cell lymphoma (DLBCL) patients, aiming to identify its differential expression and prognosis in DLBCL with its subtypes; germinal center B-cell (GCB) and activated B-cell-like (ABC) and to evaluate its relation with HCV. Subjects and Methods: MiRNA-21 expression was measured using TaqMan quantitative RT-PCR in sera of 30 newly diagnosed DLBCL patients (HCV positive (n = 10), HCV negative (n = 20)) and 20 controls (HCV positive (n = 10), HCV negative (n = 10)). Results: MiRNA-21 expression was significantly higher in DLBCL patients than in control (p = 0.00). Significant positive correlations between miRNA-21 and LDH, IPI and disease stage were detected (p < 0.05). Significantly higher miRNA-21 was detected in ABC sub-type compared to GCB sub-type (p = 0.00). Higher miRNA-21 was associated with worse response (p = 0.016), 2 years overall (p = 0.017) and progression free survival with statistical significance (p= 0.003). Significantly higher miRNA-21 levels were detected in HCV positive DLBCL patients compared to HCV negative patients (p = 0.00). Higher miRNA-21 levels were detected in HCV positive ABC subtype than GCB subtype (p = 0.05). Significantly higher levels were also detected in HCV positive controls compared to HCV negative controls. Conclusion: Our study shows that miRNA-21 is over expressed in our patients with DLBCL, displaying higher levels in ABC than in GCB subtypes. MiRNA-21 is associated with poor response to treatment and survival in DLBCL. MiRNA-21 is a potential marker of necro-inflammation independent of its role in tumorogenesis, showing higher expression in HCV positive DLBCL patients compared to none hepatitis patients.
KeywordsDiffuse Large B-Cell LymphomamicroRNA-21Hepatitis C VirusGerminal Center-BActivated B-Cell-Like
De Tullio, G., De Fazio, V., Sgherza, N., Minoia, C., Serratì, S., Merchionne, F., et al. (2014) Challenges and Opportunities of MicroRNAs in Lymphomas. Molecules, 19, 14723-14781. https://doi.org/10.3390/molecules190914723
De Yébenes, V.G., Bartolomé-Izquierdo, N. and Ramiro, A.R. (2013) Regulation of B-Cell Development and Function by MicroRNAs. Immunological Reviews, 253, 25-39. https://doi.org/10.1111/imr.12046
Tili, E., Michaille, J.J. and Croce, C.M. (2013) MicroRNAs Play a Central Role in Molecular Dysfunctions Linking Inflammation with Cancer. Immunological Reviews, 253, 167-184. https://doi.org/10.1111/imr.12050
Fu, X., Han, Y., Wu, Y., Zhu, X., Lu, X., Mao, F., et al. (2011) Prognostic Role of MicroRNA-21 in Various Carcinomas: A Systematic Review and Meta-Analysis. European Journal of Clinical Investigation, 41, 1245-1253. https://doi.org/10.1111/j.1365-2362.2011.02535.x
Xia, X., Yang, B., Zhai, X., Liu, X. Shen, K., Wu, Z., et al. (2013) Prognostic Role of MicroRNA-21 in Colorectal Cancer: A Meta-Analysis. PLoS ONE, 8, e80426. https://doi.org/10.1371/journal.pone.0080426
Hu, G., Tao, F., Wang, W. and Ji, K. (2016) Prognostic Value of MicroRNA-21 in Pancreatic Ductal Adenocarcinoma: A Meta-Analysis. World Journal of Surgical Oncology, 14, 82. https://doi.org/10.1186/s12957-016-0842-4
Wu, K., Li, L. and Li, S. (2015) Circulating MicroRNA-21 as a Biomarker for the Detection of Various Carcinomas: an Updated Meta-Analysis Based on 36 Studies. Tumor Biology, 36, 1973-1981. https://doi.org/10.1007/s13277-014-2803-2
Lawrie, C.H., Soneji, S., Marafioti, T., Cooper, C., Palazzo, S., Paterson, J.C., et al. (2007) MicroRNA Expression Distinguishes between Germinal Center B Cell-Like and Activated B Cell-Like Subtypes of Diffuse Large B Cell Lymphoma. International Journal of Cancer, 121, 1156-1161. https://doi.org/10.1002/ijc.22800
Chen, W., Wang, H., Chen, H., Liu, S., Lu, H., Kong, D., et al. (2014) Clinical Significance and Detection of MicroRNA-21 in Serum of Patients with Diffuse Large B-Cell Lymphoma in Chinese Population. European Journal of Haematology, 92, 407-412. https://doi.org/10.1111/ejh.12263
Lawrie, C.H., Gal, S., Dunlop, H.M., Pushkaran, B., Liggins, A.P., Pulford, K., et al. (2008) Detection of Elevated Levels of Tumour-Associated MicroRNAs in Serum of Patients with Diffuse Large B-Cell Lymphoma. British Journal of Haematology, 141, 672-675. https://doi.org/10.1111/j.1365-2141.2008.07077.x
Go, H., Jang, J.Y., Kim, P.J., Kim, Y.G., Nam, S.J., Paik, J.H., et al. (2015) MicroRNA-21 Plays an Oncogenic Role by Targeting FOXO1 and Activating the PI3K/AKT Pathway in Diffuse Large B-Cell Lymphoma. Oncotarget, 6, 15035-15049. https://doi.org/10.18632/oncotarget.3729
Bai, H., Wei, J., Deng, C., Yang, X., Wang, C. and Xu, R. (2013) MicroRNA-21 Regulates the Sensitivity of Diffuse Large B-Cell Lymphoma Cells to the CHOP Chemotherapy Regimen. International Journal of Hematology, 97, 223-231. https://doi.org/10.1007/s12185-012-1256-x
Gravitz, L. (2011) Introduction: A Smouldering Public-Health Crisis. Nature, 474, S2-S4. https://doi.org/10.1038/474S2a
Kanwal, F., Hoang, T., Kramer, J.R., Asch, S.M., Goetz, M.B., Zeringue, A., et al. (2011) Increasing Prevalence of HCC and Cirrhosis in Patients with Chronic Hepatitis C Virus Infection. Gastroenterology, 140, 1182-1188. https://doi.org/10.1053/j.gastro.2010.12.032
Motawi, T.K., Shaker, O.G., El-Maraghy, S.A. and Senousy, M.A. (2015) Serum MicroRNAs as Potential Biomarkers for Early Diagnosis of Hepatitis C Virus-Related Hepatocellular Carcinoma in Egyptian Patients. PLoS ONE, 10, e0137706. https://doi.org/10.1371/journal.pone.0137706
Li, J., Fu, R., Yang, L. and Tu, W. (2015) MiR-21 Expression Predicts Prognosis in Diffuse Large B-Cell Lymphoma. International Journal of Clinical and Experimental Pathology, 8, 15019-15024.
Peveling-Oberhag, J., Crisman, G., Schmidt, A., Döring, C., Lucioni, M., Arcaini, L., et al. (2012) Dysregulation of Global MicroRNA Expression in Splenic Marginal Zone Lymphoma and Influence of Chronic Hepatitis C Virus Infection. Leukemia, 26, 1654-1662. https://doi.org/10.1038/leu.2012.29
Swerdlow, S.H., Campo, E., Harris, N.L., Jaffe, E.S., Pileri, S.A., Stein, H., et al. (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th Edition, IARC Press, Lyon, 2.
Swerdlow, S.H., Campo, E., Pileri, S.A., Harris, N.L., Stein. H., Siebert, R., et al. (2016) The 2016 Revision of the World Health Organization Classification of Lymphoid Neoplasms. Blood, 19, 127, 2375-2390.
Hans, C.P., Weisenburger, D.D., Greiner, T.C., Gascoyne, R.D., Delabie, J., Ott, G., et al. (2004) Confirmation of the Molecular Classification of Diffuse Large B-Cell Lymphoma by Immunohistochemistry Using a Tissue Microarray. Blood, 103, 275-282. https://doi.org/10.1182/blood-2003-05-1545
Krichevsky, A.M. and Gabriely, G. (2009) MiR-21: A Small Multi-Faceted RNA. Journal of Cellular and Molecular Medicine, 13, 39-53. https://doi.org/10.1111/j.1582-4934.2008.00556.x
Medina, P.P., Nolde, M. and Slack, F.J. (2010) OncomiR Addiction in an in Vivo Model of MicroRNA-21-Induced Pre-B-Cell Lymphoma. Nature, 467, 86-90. https://doi.org/10.1038/nature09284
Li, C.H., Fu, R., Wang, Y.H., Song, W.J. and Ruan, E.B., et al. (2014) Expression and Clinical Significance of MiR-21 in Diffuse Large B Cell Lymphoma. Journal of Experimental Hematology, 22, 339-343.
Fu, R., Li, C. and Shao, Z. (2014) Aberrant Over Expression and Regulatory Mechanism of Mir-21 in Diffuse Large B Cell Lymphoma. Blood, 124, 5171-5175.
Zajdel, M., Rymkiewicz, G., Chechlinska, M., Blachnio, K. and Pienkowska-Grela, B., Grygalewicz, B., et al. (2015) MiR Expression in MYC-Negative DLBCL/BL with Partial Trisomy 11 Is Similar to Classical Burkitt Lymphoma and Different from Diffuse Large B-Cell Lymphoma. Tumor Biology, 36, 5377-5388. https://doi.org/10.1007/s13277-015-3203-y
Munch-Petersen, H.D., Ralfkiaer, U., Sjö, L.D., Hother, C., Asmar, F., Nielsen, B.S., et al. (2015) Differential Expression of MiR-155 and MiR-21 in Tumor and Stroma Cells in Diffuse Large B-Cell Lymphoma. Applied Immunohistochemistry & Molecular Morphology, 23, 188-195. https://doi.org/10.1097/PAI.0000000000000073
Roehle, A., Hoefig, K.P., Repsilber, D., Thorns, C., Ziepert, M., Wesche, K.O., et al. (2008) MicroRNA Signatures Characterize Diffuse Large B-Cell Lymphomas and Follicular Lymphomas. British Journal of Haematology, 142, 732-744. https://doi.org/10.1111/j.1365-2141.2008.07237.x
Vannata, B., Arcaini, L. and Zucca, E. (2016) Hepatitis C Virus-Associated B-Cell Non-Hodgkin’s Lymphomas: What Do We Know? Therapeutic Advances in Hematology, 7, 94-107. https://doi.org/10.1177/2040620715623924
Marquez, R.T., Bandyopadhyay, S., Wendlandt, E.B., Keck, K., Hoffer, B.A., Icardi, M.S., et al. (2010) Correlation between MicroRNA Expression Levels and Clinical Parameters Associated with Chronic Hepatitis C Viral Infection in Humans. Laboratory Investigation, 90, 1727-1736. https://doi.org/10.1038/labinvest.2010.126
Gragnani, L., Piluso, A., Fognani, E and Zignego, A.L. (2015) MicroRNA Expression in Hepatitis C Virus-Related Malignancies: A Brief Review. World Journal of Gastroenterology, 21, 8562-8568. https://doi.org/10.3748/wjg.v21.i28.8562
Bihrer, V., Waidmann, O., Friedrich-Rust, M., Forestier, N., Susser, S.,Haupenthal, J., et al. (2011) Serum MicroRNA-21 as Marker for Necroinflammation in Hepatitis C Patients with and without Hepatocellular Carcinoma. PLoS ONE, 6, e26971. https://doi.org/10.1371/journal.pone.0026971
Cermelli, S., Ruggieri, A., Marrero, J.A., Ioannou, G.N. and Beretta, L. (2011) Circulating MicroRNAs in Patients with Chronic Hepatitis C and Non-Alcoholic Fatty Liver Disease. PLoS ONE, 6, e23937. https://doi.org/10.1371/journal.pone.0023937
Harfoush, R., Meheissen, M., Elwafa, R. and Elwazzan, D. (2016) The Role of Circulating MicroRNAs as Markers of Disease Progression in Hepatitis C Virus Infected Egyptian Patients. Advances in Microbiology, 6, 320-331. https://doi.org/10.4236/aim.2016.64031